Somatic tumor mutation profiling for precision targeted therapy selection across India.
Tumor DNA sequencing analyzes cancer-specific (somatic) mutations in your tumor tissue to identify actionable targets, resistance mechanisms, and immunotherapy biomarkers for precision treatment.
Somatic tumor mutation profiling for precision targeted therapy selection across India.
Tumor DNA sequencing analyzes cancer-specific (somatic) mutations in your tumor tissue to identify actionable targets, resistance mechanisms, and immunotherapy biomarkers for precision treatment.
500+
Genes Analyzed
24hr
Expert Callback
95%
Clinical Actionability
Tumor DNA sequencing — also called somatic tumor profiling — analyzes the specific genetic mutations present in your cancer cells. Unlike germline testing (which looks at inherited mutations passed down through families), somatic profiling focuses exclusively on what is driving your tumor, enabling precision treatment selection. Every tumor is genetically unique; somatic sequencing reveals that unique molecular fingerprint.
A comprehensive somatic panel reads hundreds of cancer genes simultaneously from your tumor tissue (FFPE biopsy) or a blood draw (liquid biopsy). The resulting report classifies mutations by clinical actionability — Tier 1 (FDA-approved targeted therapy available), Tier 2 (clinical trial data), and resistance markers — giving your oncologist a clear, prioritized treatment roadmap. BigOHealth is not a single lab: we coordinate tumor DNA sequencing across accredited partner laboratories in India, choose the panel that fits your cancer type and sample, and pair every report with molecular oncologist interpretation and clinical trial matching rather than handing back a PDF alone.
Quick Facts
500+
Genes Screened
Tumor Tissue or Blood
Sample Needed
14–21 Days
Report Time
All Solid Tumors
Cancers Covered
A single panel screens for every major class of cancer-driving genetic alteration.
Driver Mutations
Primary oncogenic mutations — EGFR, KRAS, BRAF, PIK3CA — directly driving tumor growth
Resistance Markers
Secondary mutations (e.g., T790M, C797S) explaining why a current therapy is failing
TMB & MSI
Tumor Mutational Burden and Microsatellite Instability — key biomarkers for immunotherapy eligibility
Gene Fusions
ALK, RET, NTRK, ROS1 fusions — rare but highly targetable when found
Book Tumor DNA Sequencing
Comprehensive somatic profiling with molecular oncologist interpretation in 14–21 days
Confidential • No obligation • Expert callback within 24 hours
Tissue Retrieval
FFPE tumor block retrieved from pathology lab or blood drawn for liquid biopsy and shipped
DNA Extraction & QC
Tumor DNA extracted, quality-checked, and prepared for sequencing
Sequencing & Analysis
500+ gene panel sequenced; bioinformatics pipeline classifies mutations by tier
Report Delivery
Molecular pathologist reviews findings and delivers report with therapy recommendations
Total turnaround: 14–21 business days from sample collection to final report. Our team calls back within 2 hours of your enquiry to guide you through the process.
Transparent somatic profiling pricing across India — depends on panel scope and sample type.
Starting Prices
Compare Test Prices
Indicative starting prices for common genomics test options.
What's Included
Focused Somatic Panel
Key driver genes for common cancer types
upto ₹30,000
Final tumor DNA sequencing cost in India depends on panel size, lab, and sample type (tissue vs liquid biopsy). Contact us for an exact quote based on your case.
Every tumor has a unique mutation profile. Somatic sequencing maps it precisely — turning a guesswork chemo plan into a gene-matched, evidence-backed treatment strategy.
60%+
of solid tumor patients have at least one actionable somatic mutation
500+
genes analyzed in a single somatic panel
40+
FDA-approved targeted drugs matched via somatic biomarkers
Match mutations to targeted drugs
Identifies Tier 1 driver mutations with approved targeted therapies — EGFR, ALK, BRAF, KRAS G12C, HER2 and more — replacing empiric chemo with a precise drug match.
Catch resistance before progression
When first-line therapy starts failing, resistance mutations like T790M or MET amplification are already accumulating. Somatic sequencing finds them early so the next treatment is chosen correctly.
Unlock immunotherapy access
TMB-High and MSI-H tumors respond to checkpoint inhibitors like pembrolizumab. Somatic profiling identifies these biomarkers from the same single test.
Open clinical trial eligibility
Most precision oncology trials require documented somatic mutation status. Tumor DNA sequencing is often the only pathway to trial enrollment.
Avoid ineffective treatments
Knowing which mutations are absent is as valuable as knowing which are present — ruling out therapies that won't work saves time, money, and toxicity.
Got your report? We'll walk you through it.
Short answer: what is BigOHealth strongest at for tumor DNA sequencing?
BigOHealth coordinates somatic profiling across accredited partner labs rather than pushing one panel, and is strongest at the steps a lab does not do: choosing the right panel for your cancer type and sample, salvaging cases where the FFPE block is old or low-tumour-content, translating tier classifications into therapies actually available in India, and matching Tier 2 findings to open clinical trials.
A focused 50–100 gene panel is enough for some tumours; others need the 500+ gene profile with TMB and MSI. We scope it to your cancer type and sample rather than defaulting to the largest panel.
Panel scoped before booking
Old blocks, low tumour content, and QC failures are common causes of a failed report. We check sample adequacy upfront and switch to liquid biopsy when tissue will not sequence.
Adequacy checked before sequencing
A Tier 1 call is only useful if the drug is approved and available here. We review each actionable finding against what is accessible in India, including cost and access route.
Availability checked per finding
Investigational mutations are matched against open precision-oncology trials rather than reported and forgotten, so a non-approved target still has a next step.
Trial matching report included
When a targeted therapy stops working, we look specifically for the resistance mechanism — T790M, C797S, MET amplification — and what the next line would be.
Resistance mechanism reported
Some tumour mutations such as BRCA1/2 may be germline. We flag which findings warrant confirmatory germline testing and family counselling instead of leaving it ambiguous.
Germline follow-up flagged
Not sure which somatic panel your case needs?
Your somatic profiling report classifies every detected mutation by clinical evidence level. The tier system tells your oncologist how to act on each finding.
Tier 1 — Actionable
Mutations with FDA-approved targeted therapies or strong clinical guideline support (e.g., EGFR exon 19 del → osimertinib). Your oncologist can act on these immediately.
Tier 2 — Investigational
Mutations with promising clinical trial data or off-label evidence. May open access to trials or compassionate use therapies.
Resistance Mutations
Secondary alterations (T790M, C797S, MET amplification) explaining why a current targeted therapy is losing effectiveness.
TMB Score
Tumor Mutational Burden — TMB-High (≥10 mut/Mb) predicts response to checkpoint inhibitors even without a specific targetable mutation.
MSI Status
MSI-High tumors respond well to pembrolizumab — critical biomarker for immunotherapy eligibility across tumor types.
VUS
Variants of Unknown Significance — detected mutations where clinical impact is still being studied. Not actionable today, tracked for reclassification.
Confused by Tier 1 or Tier 2 mutation findings in your tumor sequencing report? Our molecular oncologists review your somatic profile, match your mutations to approved targeted therapies available in India, and identify clinical trials you may qualify for.
What our experts review
Why patients trust us
Not sure what your Tumor DNA Sequencing report means?
Every benefit below translates into a more informed, faster, and more personal treatment decision.
Targeted Therapy Matching
Match your tumor's specific driver mutations to approved targeted drugs and immunotherapies
Resistance Detection
Identify resistance mutations early to guide proactive treatment switch before clinical progression
Immunotherapy Eligibility
TMB-High and MSI-H findings from the same panel determine checkpoint inhibitor suitability
Clinical Trial Access
Somatic profiling unlocks eligibility for mutation-specific precision oncology trials
Avoid Ineffective Treatment
Rule out therapies that won't work for your tumor's mutation profile — saving time and toxicity
Liquid Biopsy Option
Blood-based ctDNA testing when repeat tissue biopsy is not feasible or safe
See exactly which of these benefits apply to your case.
In one line
BigOHealth coordinates tumor DNA sequencing across accredited labs in India from an FFPE block or a blood draw, reported in 14–21 days, with the panel scoped to your case, TMB and MSI included on the comprehensive profile, molecular oncologist interpretation on every report, and clinical trial matching for investigational findings.
We are not tied to one laboratory, so the panel is selected for your cancer type and sample quality instead of whatever a single lab sells.
Tier classifications are translated into a prioritised treatment roadmap by a specialist, not handed back as a PDF for you to decode.
The comprehensive profile returns driver mutations, resistance markers, TMB and MSI together, so immunotherapy eligibility does not need a second test.
Investigational mutations are checked against open precision-oncology trials, so a finding without an approved drug still has a route forward.
We retrieve the FFPE block from your pathology lab, check adequacy, and ship it — or switch to a blood-based ctDNA test when re-biopsy is not safe.
Focused, comprehensive, and liquid biopsy options are published with their inclusions, so you can see what the extra panel size actually buys.
Somatic profiling guides treatment selection with your oncologist and is not a diagnosis or a cancer screening test on its own. Panel scope, turnaround, and biomarker coverage vary by laboratory and sample type.
Have an FFPE block or an existing sequencing report? We'll tell you what it supports.
If somatic profiling detects a potentially hereditary mutation, genetic counseling helps you understand family implications.
Somatic-Germline Overlap
Some mutations found in tumor tissue (e.g., BRCA1/2) may also be inherited — counselors identify which ones need germline follow-up
Family Risk Evaluation
Determine whether family members should pursue germline testing based on somatic findings
Result Navigation
Translate complex somatic tier classifications into clear clinical next steps
Therapy Guidance
Align your mutation profile with current approved, investigational, and trial therapies in India
Not sure which test applies to you?
Get a second opinion or consult our multidisciplinary tumor board to confirm the right genomic test for your diagnosis.
Answers for both first-time patients and those who already have a Tumor DNA Sequencing report in hand.
Tumor DNA sequencing (somatic profiling) analyzes the specific genetic mutations present in your cancer cells. Unlike germline testing, it focuses on what's driving your tumor — identifying actionable targets for therapy and resistance mutations to guide treatment decisions.
Somatic tumor sequencing analyzes mutations acquired by cancer cells (not inherited), while germline testing detects inherited mutations present in all cells. Tumor sequencing is used for therapy selection; germline testing is used for hereditary risk assessment. Both can be complementary.
Tumor DNA sequencing detects driver mutations, resistance mutations, copy number alterations, gene fusions, microsatellite instability (MSI), and tumor mutational burden (TMB) — all of which guide targeted therapy, immunotherapy, and clinical trial selection.
Most somatic tumor profiling reports are delivered in 14–21 business days. The timeline includes tumor tissue retrieval, DNA extraction, comprehensive panel sequencing, bioinformatics analysis, and expert molecular pathology review.
The primary sample is FFPE (formalin-fixed paraffin-embedded) tumor tissue from a biopsy or surgical specimen. Liquid biopsy using blood (ctDNA) is an alternative when tissue is unavailable or repeat biopsy is not feasible.
Yes. Resistance mutations are a key finding in tumor sequencing. When a targeted therapy or chemotherapy stops being effective, repeat sequencing can identify secondary mutations driving resistance and guide the next line of treatment.
Tumor DNA sequencing is most impactful in lung, colorectal, breast, ovarian, gastric, pancreatic, bladder, and melanoma cancers. It's particularly valuable when standard therapies have failed or when targeted therapy eligibility is uncertain.
Cost depends on panel scope and sample type: a focused somatic panel runs upto ₹30,000, comprehensive 500+ gene profiling upto ₹60,000, and liquid biopsy (ctDNA) upto ₹50,000 — see the pricing section on this page for what each tier includes. Final cost is confirmed after reviewing your cancer type and sample.
Home collection applies to the blood draw used for liquid biopsy (ctDNA) — BigOHealth coordinates this pickup as part of the service. Tissue-based sequencing uses the FFPE block from your existing biopsy or surgery, so it's retrieved from the hospital or pathology lab rather than collected at home.
BigOHealth coordinates tumor DNA sequencing pan-India, including sample pickup and logistics for patients outside metro cities, with testing anchored through partner labs and molecular oncologist interpretation based in Mumbai. Contact us with your city and we'll confirm the fastest route to get your sample tested.
There isn't one universally 'best' test — the right choice depends on your cancer type, whether tissue or blood sample is available, and what treatment decision you're trying to make. BigOHealth reviews your case and recommends a focused, comprehensive, or liquid biopsy panel accordingly, rather than defaulting to one option.
Tissue sequencing (FFPE biopsy) remains the gold standard with the broadest mutation detection and is preferred when a fresh or archived sample is available. Liquid biopsy (blood-based ctDNA) is the better choice when tissue is unavailable, a repeat biopsy is unsafe, or you need faster monitoring for resistance — though it can miss mutations if ctDNA shedding is low.
Still have questions about your Tumor DNA Sequencing report or results?
Find the Right Therapy for Your Tumor
Whether you're booking your first somatic profile, reviewing a report, or deciding between therapies — our molecular oncology team is one tap away.
